Targeting the Cellular Origin of Organ Fibrosis  by Kim, Johnny & Braun, Thomas
Cell Stem Cell
PreviewsTargeting the Cellular Origin of Organ FibrosisJohnny Kim1 and Thomas Braun1,*
1Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany
*Correspondence: thomas.braun@mpi-bn.mpg.de
http://dx.doi.org/10.1016/j.stem.2014.12.008
Organ fibrosis after injury, which can significantly compromise tissue function, is in part due to proliferation
of fibroblasts and myofibroblasts of unclear cellular origin. Now in Cell Stem Cell, Kramann et al. (2015)
show that perivascular Gli1+ mesenchymal-stem-cell-like cells generate a large fraction of myofibroblasts
in disease conditions.Fibroblasts are the most common cells of
connective tissue and are essential for
maintaining the structural integrity and
function of organs including lung, skeletal
muscle, kidney, and heart. After organ
injury, fibroblasts become activated and
produce growth factors and extracellular
matrix (ECM) proteins such as collagen
and can differentiate into myofibroblasts,
which exhibit features of both fibroblasts
and smooth muscle. These changes can
lead to a condition termed organ fibrosis.
Although a moderate fibrotic response is
crucial to compensate for loss of tissue
resulting from the damaging insult, exces-
sive organ fibrosis can substantially inhibit
proper organ function and contribute
significantly to pathogenesis of a variety
of diseases such as cardiac hypertrophy,
idiopathic pulmonary fibrosis, or tubuloin-
terstitial fibrosis of the kidney (Wynn,
2008). The cellular origin of the fibro-
blastic cells that drive organ fibrosis, how-
ever, has been controversial. In this issue
of Cell Stem Cell, Kramann et al., (2015)
show that perivascular Gli1+ mesen-
chymal stem cell (MSC)-like cells are
major contributors to pathophysiological
organ fibrosis.
Conflicting reports have suggested
that pathogenic myofibroblasts may arise
from tissue-resident fibroblasts, endothe-
lial or epithelial cells, or tissue-resident
or circulating MSC populations (Wynn,
2008). To address these issues, Kramann
and colleagues utilized elegant cell tracing
and ablation approaches combined with
in vitro analyses to demonstrate that a
subpopulation of PDGFRß+/Gli1+ cells
provides a large share of a-smooth mus-
cle actin (SMA)+myofibroblasts in various
solid organs after different types of injury
(Figure 1). PDGFRß is a marker of
vessel-associated cells called pericytes
but is also expressed by mesenchymalcells (Henderson et al., 2013). Despite
accumulation of PDGFRß+ cells in the
interstitium, their functional contribution
to kidney fibrosis has been questioned
(Humphreys et al., 2010; LeBleu et al.,
2013; Song et al., 2005). Kramann et al.
performed careful in vivo cell tracing ex-
periments to show that a subpopulation
of PDGFRß+-expressing Gli1+ cells form
a perivascular network of MSC-like cells.
These cells express several characteristic
MSC markers, including 3G5, Nestin, and
PDGFRa, and they differentiate into bone,
cartilage, and fat cells in vitro. PDGFRß+/
Gli1+ cells show increased colony form-
ing unit capability compared to other
PDGFRß+ cells, and in vitro experiments
suggest that Gli1 may be required for their
self-renewal.
The authors next assessed the role
of PDGFRß+/Gli1+ cells during organ
fibrosis using lineage tracing. Although
PDGFRß+/Gli1+ cells are present at sur-
prisingly low numbers under homeostatic
conditions, they expand rapidly after
injury. Depending on the organ type and
injury model, PDGFRß+/Gli1+ cells were
found to contribute 37%–60% of myofi-
broblasts found in fibrotic lungs, liver,
heart, and kidneys while retaining expres-
sion of PDGFRß (Kramann et al., 2015).
NG2 has been proposed as a marker for
pericytes and the majority of MSCs and
thus may be expressed in PDGFRß+/
Gli1+ cells. The authors found that
although resting Gli1+ cells do not ex-
press NG2, NG2 expression is present in
many PDGFRß+/Gli1+ cells that partici-
pate in the formation of tube-like struc-
tures after myocardial infarction. These
findings indicate that PDGFRß+/Gli1+
cells not only contribute to fibrosis but
also to the formation of new vessels.
Kramann and colleagues next asked
whether the Gli1+ MSC-like cells thatCell Stem Celgenerate fibrotic myofibroblasts reside
in the damaged tissue or circulate and
home after injury. They addressed this
question by transplanting whole bone
marrow from Gli1+ fate-labeled donors
into mismatched CD45 antigen variant re-
cipients and monitoring MSC recruitment
after injury. In conjunction with parabiosis
experiments, these results demonstrated
that Gli1+ cells were not derived from
circulating or bone-marrow-resident cells
and suggested instead that pathogenic
myofibroblasts arise from tissue-resident
perivascular cells. Finally, the authors
tested the functional contribution of
Gli1+ cells in organ fibrosis through diph-
theria-toxin-mediated ablation of these
cells. Ablation of Gli1+ cells was found
to significantly reduce fibrotic scarring in
both heart and kidney injury models and
to increase left ventricular function in a
model of chronic heart injury.
Data from several studies (Humphreys
et al., 2010; LeBleu et al., 2013; Song
et al., 2005) suggest that fibrinogenic cells
are derived from different progenitor cells
whose relative pathophysiological con-
tribution might differ depending on the
respective condition. Consistently, Kra-
mann and co-workers observed that not
all a-SMA+ myofibroblasts in fibrotic tis-
sues were derived from Gli1+ cells, sup-
porting the existence of other types of
pro-fibrotic progenitors. Because Kra-
mann et al. observed an amelioration of
organ fibrosis after ablation of Gli1-
expressing cells, it is conceivable that
Gli1+ cells might play an important role
in the recruitment or control of such addi-
tional pro-fibrotic cell populations. Their
finding that a Gli1-expressing subset of
PDGFRß+ cells contributes to organ
fibrosis offers a refined view resolving
previous controversies about the fate of
PDGFRß+ cells. Undoubtedly, it will bel 16, January 8, 2015 ª2015 Elsevier Inc. 3
Figure 1. Simplified Model of the Cellular Origin of Organ Fibrosis
A rare population of PDGFRß+/Gli1+ cells forms a network of perivascular MSC-like cells in multiple
organs. In disease conditions, PDGFRß+/Gli1+ cells are activated, expand, and differentiate to a-SMA-ex-
pressing myofibroblasts that secrete ECM components such as collagen. Other cell types, including
tissue resident fibroblasts and circulating MSCs, might also contribute to organ fibrosis to a varying
degree.
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Previewsinteresting to see whether distinct sub-
sets of Gli1+ cells contribute to angiogen-
esis and fibrosis or whether Gli1+ cells
have multi-lineage differentiation poten-
tial dictated by local signaling cues. In
this context, it is important to realize that
the use of a limited set of markers might
not be sufficient to fully define biological
properties of distinct cell populations.
Further analysis using emerging single-
cell profiling techniquesmight unveil addi-
tional diversity and more precise views
about the origin and properties of biolog-
ically relevant progenitor cells.
Gli1 is a transcription factor that medi-
ates Hedgehog (Hh) signaling (Hui and
Angers, 2011), raising the question of the
functional role of Gli1 in the pro-fibrotic
response. Further insights into themecha-4 Cell Stem Cell 16, January 8, 2015 ª2015 Enisms that establish PDGFRb+/Gli1+
cellular identity, maintain Gli1 expression,
and inhibit proliferation under homeostatic
conditions will be helpful in the develop-
ment of therapeutic strategies for restrict-
ing hyperactive proliferation and prevent-
ing pathological fibrosis. The localization
of PDGFRb+/Gli1+ cells in a perivascular
network around capillaries might offer
additional clues about the nature of the
signals regulating the behavior of these
cells, implicating signals from within the
perivascular niche or circulating factors.
Identification of such factors may also
clarify the acclaimed positive role of Shh
signaling in reducing fibrosis and preser-
ving cardiac function after myocardial
infarction (Kusano et al., 2005). These
latter results seem to stand in contrast tolsevier Inc.those of Kramann et al. demonstrating
that ablation of PDGFRß+/Gli1+ cells
ameliorates fibrosis and improves organ
function after injury, but they might be ex-
plained by a pro-angiogenic role of Shh
under certain conditions.
Importantly, it will be necessary to eval-
uate whether ablation of PDGFRß+/Gli1+
cells has long-term negative side-effects,
such as vessel destabilization or fragility
of the myocardium, especially in condi-
tions such as myocardial infarction that
require formation of stable scars. Although
future work is required to address these
and other issues, overall these current
findings suggest that inhibiting or ablating
Gli1+ stem cells may have putative thera-
peutic value for the prevention of organ
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